Wells Fargo: White House Healthcare Plan Faces Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Wells Fargo says the "The Great Healthcare Plan" released by the White House, which calls on Congress to implement reforms affecting premiums, pharmacy benefit managers, and drug pricing, will likely face a difficult path forward. In addition, lack of "new onerous proposals could be viewed as positive" for the healthcare services group, the analyst tells investors in a research note. Names covered by the analyst include CVS Health (CVS), Cardinal Health (CAH), BrightSpring Health (BTSG), Cigna (CI), Centene (CNC), Humana (HUM), McKesson (MCK), Tenet Healthcare (THC) and UnitedHealth (UNH).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTSG
Wall Street analysts forecast BTSG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTSG is 43.20 USD with a low forecast of 40.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.050
Low
40.00
Averages
43.20
High
50.00
Current: 39.050
Low
40.00
Averages
43.20
High
50.00
About BTSG
BrightSpring Health Services, Inc. provides home and community-based pharmacy and health solutions for populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, it provides integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. With a focus on senior and specialty patients, the Company’s platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to medicare, medicaid, and commercially insured populations. It delivers services through two reportable segments: Pharmacy Solutions and Provider Services. It provides pharmacy services when and where demanded and as required by customers and patients in their homes and communities, often in coordination with its provider’s services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
Continue Reading
Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.
Continue Reading